Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.

Yuka Kato,Taku Noumi,Kazuhiko Saeki,Kiichiro Ninomiya,Toshio Kubo,Masanori Fujii,Kammei Rai,Eiki Ichihara,Kadoaki Ohashi,Masahiro Tabata,Katsuyuki Hotta,Toshiyuki Kozuki,Yoshinobu Maeda,Katsuyuki Kiura

Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.

2021

Yuka Kato
Taku Noumi
Kazuhiko Saeki
Kiichiro Ninomiya
Toshio Kubo
Masanori Fujii
Kammei Rai
Eiki Ichihara
Kadoaki Ohashi
Masahiro Tabata
Katsuyuki Hotta
Toshiyuki Kozuki
Yoshinobu Maeda
Katsuyuki Kiura

e20590Background: For patients with extensive-disease small cell lung cancer (ED-SCLC), amrubicin monotherapy is an important therapy in the treatment of recurrence, but there has been no adequate ...

Keywords:

Medicine
Internal medicine
Lung cancer
non small cell
combination chemotherapy
Amrubicin
Oncology
second line treatment
Extensive Disease
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations